Le Lézard
Classified in: Health
Subject: FDA

VGI Medical, LLC Announces FDA Clearance of the Novel 3D Printed SiJoin® T3 Implant System, for Sacroiliac Joint Transfixation


VGI Medical, LLC announces it has received 510(k) clearance from the United States Food and Drug Administration to market the transfixing SiJoin®  Triangular Trabecular Titanium (T3) Implant System. The SiJoin®  T3 System is the next evolution of the successful SiJoin®  Direct Posterior Fusion Device, proven for over 10 years. VGI's superior engineering and testing has allowed them to design a titanium alloy implant for use in alleviating sacroiliac joint pain and create a simplified process for the surgeon.

LARGO, Fla., April 18, 2023 /PRNewswire-PRWeb/ -- VGI Medical, LLC announces the new US FDA 510(k) cleared SiJoin®  Triangular Trabecular Titanium (T3) Implant System. The transfixing SiJoin®  T3 Implant is made from Ti-6AI-4V ELI titanium alloy using an additive manufacturing process, where the trabecular construction is engineered to mimic cancellous bone structure. The SiJoin®  T3 Implant is engineered with a dual geometric shape designed to be implanted within the plane of the SI joint, simultaneously positioned within the cortical walls of the ilium and sacrum, providing high surface area contact for transfixation. The implant is held against rotation via the stabilizer fins positioned between the opposing ilium and sacrum surfaces, and the non-circular cross-section of the main body. The novel design of the SiJoin®  T3 Implant fixes the ilium and sacrum relative to one another, maintaining the anatomical spacing of the SI joint, providing mechanical support by transfixing the SI joint while biologic fusion occurs.

The SiJoin®  T3 System uses a less destructive posterior approach to achieve transfixation, in which two small incisions may be used to access the SI joint. Specialized SiJoin®  directional instrumentation deploys the implant into the SI joint, positioned across the joint, within the ilium and sacrum for transfixing of the SI joint. Biomechanical performance testing conducted by Dr. Goel at The University of Toledo demonstrates improved performance to lateral systems by taking advantage of the ?leverage arm? concept. Benefits for the surgeon include small incisions and specialized instruments requiring less operating room time and faster patient recovery. The benefit to the patient is less surgical trauma and less pain. Tov Vestgaarden, Ph.D., President and CEO of VGI Medical stated, ?VGI has been in the SI fusion market for over 10 years with a patented procedure and patented product that is proven to help patients increase their quality of life. We are excited to provide an advancement of this existing technology by incorporating the benefits of a 3D printed titanium implant?.

Pull Quote

Biomechanical performance testing conducted by Dr. Goel at The University of Toledo demonstrates improved performance to lateral systems by taking advantage of the ?leverage arm? concept.

Media Contact

Tov Vestgaarden, VGI Medical, LLC, 1 7275651235, [email protected], www.vgimedical.com

LinkedIn

 

SOURCE VGI Medical, LLC


These press releases may also interest you

at 06:00
A native born and trained Brazilian oncologist is in the forefront of a new era in the treatment of cancer patients with cutting edge proton therapy medical technology developed in Israel by P-Cure. "It is my dream to be able to bring the P-Cure...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced results from a new analysis of the ATLAS trial, which estimates using Kaplan Meier...

4 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from a real-world patient cohort review of JELMYTO...

4 mai 2024
Women's Heart Health Month is recognized every May and is focused on raising awareness about cardiovascular health among women. It aims to educate women about the risks, symptoms, and prevention of heart disease, which is the leading cause of death...

4 mai 2024
RaySearch Laboratories AB (publ) and C-RAD are pleased to announce a collaboration agreement, aiming at jointly developing innovative solutions and products to enhance the quality of radiation therapy. The focus of the collaboration is to...

4 mai 2024
SecondOpinionExpert, Inc. (SOE), a leading healthcare technology company, announced today that OC Fertility® + OC Biogenix® located in Newport Beach, Orange County, California will join SOE's expert panel to provide second opinions for fertility...



News published on and distributed by: